首页> 外国专利> STEROL DERIVATIVES AND USE THEREOF FOR TREATING DISEASES INVOLVING TRANSFORMED ASTROCYTE CELLS OR FOR TREATING MALIGNANT HAEMOPATHIES

STEROL DERIVATIVES AND USE THEREOF FOR TREATING DISEASES INVOLVING TRANSFORMED ASTROCYTE CELLS OR FOR TREATING MALIGNANT HAEMOPATHIES

机译:固醇衍生物并将其用于治疗涉及转化的星形胶质细胞的疾病或治疗恶性血液病

摘要

Sterol derivatives of (I) are new. Sterol derivatives of formula (I) are new. A1 : -(R1) n; R1 : amino acid residue bonded to its C-terminal end (optionally substituted by -C-(O)-R2); n : 1-3; R2 : mono- or multi- cyclic 6-14C arylalkyl or mono- or multi- cyclic 5-14C heteroarylalkyl including heteroatoms, mono- or multi- cyclic 6-14C arylalkyloxy or mono- or multi- cyclic 5-14C heteroarylalkyloxy including heteroatoms, -C-(O)-NH-R3 or -C-(S)-NH-R3; R3 : H, linear or branched 1-12C-alkyl (optionally substituted by OR, NRR4, NHR or SR), aryl (optionally substituted by OR, NRR4, NHR or SR), acyl, formyl, sulfonyl, sulfinyl, silyl (optionally substituted by mono- or multi- cyclic 6-14C-aryl or linear or branched 1-6C alkyl), allyl, sugar, -C-(O)-OR5, amide, thioamide, sulfonamide or -C(O)-R6; R, R4 : H, 1-12C alkyl or optionally substituted aryl; R5 : linear or branched 1-12C-alkyl (optionally substituted by OR, NRR4, NHR or SR); R6 : saturated 5-14C heterocycle comprising 1 or 2 heteroatoms (optionally substituted by linear or branched 1-6C-alkyl or OR, NRR4, NHR or SR); B1 : -C(O)-R7 or aryl (optionally substituted by OR, NRR4, NHR or SR); R7 : H, 1-12C-alkyl, preferably linear or branched 1-6C-alkyl (optionally substituted by OR, NRR4, NHR or SR) or OR8; and R8 : 1-12C-alkyl, preferably linear or branched 1-6C-alkyl. Independent claims are included for: (1) preparing (I); and (2) a composition comprising (I) a carrier. [Image] ACTIVITY : Cytostatic. MECHANISM OF ACTION : None given.
机译:(I)的甾醇衍生物是新的。式(I)的甾醇衍生物是新的。 A1:-(R1)n; R1:键合至其C末端的氨基酸残基(任选地被-C-(O)-R2取代); n:1-3; R2:单环或多环6-14C芳基烷基或单环或多环5-14C杂芳基烷基,包括杂原子,单环或多环6-14C芳基烷氧基或单环或多环5-14C杂芳基烷氧基,包括杂原子, -C-(O)-NH-R3或-C-(S)-NH-R3; R3:H,直链或支链的1-12C-烷基(任选地被OR,NRR4,NHR或SR取代),芳基(任选地被OR,NRR4,NHR或SR取代),酰基,甲酰基,磺酰基,亚磺酰基,甲硅烷基(任选地被单环或多环6-14C-芳基或直链或支链的1-6C烷基,烯丙基,糖,-C-(O)-OR5,酰胺,硫代酰胺,磺酰胺或-C(O)-R6取代; R,R4:H,1-12C烷基或任选取代的芳基; R5:直链或支链的1-12C-烷基(任选地被OR,NRR4,NHR或SR取代); R6:包含1或2个杂原子的饱和5-14C杂环(任选地被直链或支链的1-6C-烷基或OR,NRR4,NHR或SR取代); B1:-C(O)-R7或芳基(任选地被OR,NRR4,NHR或SR取代); R7:H,1-12C-烷基,优选直链或支链的1-6C-烷基(任选地被OR,NRR4,NHR或SR取代)或OR8; R8:1-12C-烷基,优选直链或支链的1-6C-烷基。独立索赔包括:(1)准备(I); (2)包含(I)载体的组合物。 [图像]活动:细胞静止。作用机理:未给出。

著录项

  • 公开/公告号HRP20180345T1

    专利类型

  • 公开/公告日2018-06-01

    原文格式PDF

  • 申请/专利权人 BETA INNOV;

    申请/专利号HR2018P000345T

  • 申请日2018-02-26

  • 分类号C07J9;A61K31/575;A61P35;C07J41;C07J75;

  • 国家 HR

  • 入库时间 2022-08-21 12:52:40

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号